These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36967362)

  • 1. Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    Moschini M; Salonia A; Briganti A; Montorsi F
    Eur Urol; 2023 Oct; 84(4):439-440. PubMed ID: 36967362
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. Letter.
    Peng CK; Sung WW; Chen SL
    J Urol; 2023 May; 209(5):845-846. PubMed ID: 36893470
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    Lee HW; Lee HH; Park EY; Park WS; Kim SH; Joung JY; Chung J; Seo HK
    J Urol; 2023 Jan; 209(1):131-139. PubMed ID: 36250938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
    J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
    Lee CT; Barocas D; Globe DR; Oefelein MG; Colayco DC; Bruno A; O'Day K; Bramley T
    J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
    Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
    Shapiro O; Jones K; Wang C; Landas S; Haas GP
    Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
    Ersoy H; Yaytokgil M; Karakoyunlu AN; Topaloglu H; Sagnak L; Ozok HU
    Drug Des Devel Ther; 2013; 7():1-6. PubMed ID: 23300343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.
    Lenis AT; Asanad K; Blaibel M; Donin NM; Chamie K
    BMC Urol; 2018 Oct; 18(1):93. PubMed ID: 30355350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
    Krege S; Giani G; Meyer R; Otto T; Rübben H
    J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial.
    Carrión DM; Gómez Rivas J; Aguilera Bazán A; Ballesteros Ruiz C; Álvarez-Maestro M; Ríos González E; Martínez-Piñeiro L
    Arch Esp Urol; 2021 Nov; 74(9):883-893. PubMed ID: 34726625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.